(Q38068099)

28 August 2017

1 reference

title

Improving the efficacy of RAAS blockade in patients with chronic kidney disease (English)

1 reference

28 August 2017

1

Hiddo J Lambers Heerspink

1 reference

28 August 2017

Martin H de Borst

2

1 reference

28 August 2017

Stephan J L Bakker

series ordinal

3

1 reference

28 August 2017

Gerjan J Navis

series ordinal

4

1 reference

28 August 2017

language of work or name

English

0 references

publication date

18 December 2012

1 reference

Nature Reviews Nephrology

28 August 2017

published in

1 reference

28 August 2017

volume

9

1 reference

28 August 2017

issue

2

1 reference

28 August 2017

page(s)

112-121

1 reference

Standards of medical care in diabetes--2012

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Supramaximal dose of candesartan in proteinuric renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Dual renin-angiotensin system blockade at optimal doses for proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Renal and cardio-protective effects of direct renin inhibition: a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Aldosterone, from (patho)physiology to treatment in cardiovascular and renal damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Proteinuria: Is the ONTARGET renal substudy actually off target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

The HALT polycystic kidney disease trials: design and implementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Erythropoietin is reduced by combination of diuretic therapy and RAAS blockade in proteinuric renal patients with preserved renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Effects of antiproteinuric intervention on elevated connective tissue growth factor (CTGF/CCN-2) plasma and urine levels in nondiabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Late-onset renal failure from angiotensin blockade (LORFFAB) in 100 CKD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Haemodynamic effects of dual blockade of the renin-angiotensin system in spontaneously hypertensive rats: influence of salt

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

A low-sodium diet potentiates the effects of losartan in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Effects of salt supplementation on the albuminuric response to telmisartan with or without hydrochlorothiazide therapy in hypertensive patients with type 2 diabetes are modulated by habitual dietary salt intake.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Effects of High- and Low-Sodium Diets on Ambulatory Blood Pressure in Patients With Hypertension Receiving Aliskiren

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Sodium intake, ACE inhibition, and progression to ESRD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Glomerular hyperfiltration and the salt paradox in early [corrected] type 1 diabetes mellitus: a tubulo-centric view.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Short-term moderate sodium restriction induces relative hyperfiltration in normotensive normoalbuminuric Type I diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Salt reduction lowers cardiovascular risk: meta-analysis of outcome trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Sodium status and angiotensin-converting enzyme inhibition: effects on plasma angiotensin-(1-7) in healthy man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

ACE inhibition has adverse renal effects during dietary sodium restriction in proteinuric and healthy rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Combined renin-angiotensin system blockade and dietary sodium restriction impairs cardiomyocyte contractility

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

The association between dietary sodium intake, ESRD, and all-cause mortality in patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Urinary sodium and potassium excretion and risk of cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Dietary salt intake and mortality in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Benefits of dietary sodium restriction in the management of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Sodium intake and blood pressure in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Possible renoprotection by vitamin D in chronic renal disease: beyond mineral metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Elevated N-terminal pro-brain natriuretic peptide levels predict an enhanced anti-hypertensive and anti-proteinuric benefit of dietary sodium restriction and diuretics, but not angiotensin receptor blockade, in proteinuric renal patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Effect of combining ACE inhibition with aldosterone blockade on proteinuria and renal damage in experimental nephrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Dual RAS therapy not on target, but fully alive

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: a post-hoc analysis of the RENAAL and IDNT trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Radiographic contrast-induced nephropathy and patient mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Diuretic effects of angiotensin-converting enzyme inhibition: comparison of low and liberal sodium diet in hypertensive patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Moderate sodium restriction in hypertensive subjects: renal effects of ACE-inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Antiproteinuric effect predicts renal protection by angiotensin-converting enzyme inhibition in rats with established adriamycin nephrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

High Dietary Sodium Blunts Effects of Angiotensin-converting Enzyme Inhibition on Vascular Angiotensin I–to–Angiotensin II Conversion in Rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Rise in extracellular fluid volume during high sodium depends on BMI in healthy men

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.281

Moderate sodium restriction with angiotensin converting enzyme inhibitor in essential hypertension: a double blind study

31 March 2020

1 reference

12 December 2020

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)

1 reference

12 December 2020

Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) randomized trial

1 reference

12 December 2020

Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease

1 reference

12 December 2020

Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?

1 reference

12 December 2020

Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: role of sodium status

1 reference

12 December 2020

Reduced dietary salt for the prevention of cardiovascular disease

1 reference

12 December 2020

Response to angiotensin-converting enzyme inhibition is selectively blunted by high sodium in angiotensin-converting enzyme DD genotype: evidence for gene–environment interaction in healthy volunteers

1 reference

12 December 2020

K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2012.281

1 reference

28 August 2017

1 reference